dibenzo-30-crown-10: structure
ID Source | ID |
---|---|
PubMed CID | 87120 |
CHEMBL ID | 155600 |
SCHEMBL ID | 35679 |
MeSH ID | M0041867 |
Synonym |
---|
6,7,9,10,12,13,15,16,23,24,26,27,29,30,32,33-hexadecahydrodibenzo[b,q][1,4,7,10,13,16,19,22,25,28]decaoxacyclotriacontine |
dibenzo-30-crown-10, 98% |
CHEMBL155600 |
D2684 |
dibenzo-30-crown 10-ether |
17455-25-3 |
AKOS002312969 |
dibenzo(b,q)(1,4,7,10,13,16,19,22,25,28)decaoxacyclotriacontin, 6,7,9,10,12,13,15,16,23,24,26,27,29,30,32,33-hexadecahydro- |
2,3,17,18-dibenzo-1,4,7,10,13,16,19,22,25,28-decaoxacyclotriaconta-2,17-diene |
dibenzo-30-crown |
dibenzo-30-crown-10 |
dibenzo-30-crown-10-ether |
FT-0624633 |
SCHEMBL35679 |
6,7,9,10,12,13,15,16,23,24,26,27,29,30,32,33-hexadecahydrodibenzo[b,q][1,4,7,10,13,16,19,22,25,28]decaoxacyclotriacontine # |
MXCSCGGRLMRZMF-UHFFFAOYSA-N |
dibenzo[b,q][1,4,7,10,13,16,19,22,25,28]decaoxacyclotriacontin,6,7,9,10,12,13,15,16,23,24,26,27,29,30,32,33-hexadecahydro- |
DTXSID30169851 |
dibenzo[b,q][1,4,7,10,13,16,19,22,25,28]decaoxacyclotriacontin, 6,7,9,10,12,13,15,16,23,24,26,27,29,30,32,33-hexadecahydro- |
mfcd00054624 |
AS-75105 |
2,5,8,11,14,21,24,27,30,33-decaoxatricyclo[32.4.0.0(1)?,(2)?]octatriaconta-1(34),15,17,19,35,37-hexaene |
J-011008 |
2,5,8,11,14,21,24,27,30,33-decaoxatricyclo[32.4.0.015,20]octatriaconta-1(38),15,17,19,34,36-hexaene |
T70432 |
CS-0198990 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID50775 | In vitro lethal dose of compound against Eimeria tenella in chicken kidney cell cultures | 1983 | Journal of medicinal chemistry, Apr, Volume: 26, Issue:4 | Anticoccidial activity of crown polyethers. |
AID280249 | Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
AID280248 | Antiproliferative activity against SW620 cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
AID280247 | Antiproliferative activity against MiaPaCa2 cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
AID280245 | Antiproliferative activity against H460 cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
AID280246 | Antiproliferative activity against HeLa cells after 72 hrs by MTT assay | 2007 | Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5 | Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (33.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.49) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |